Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity.
Several chemotherapeutics exert immunomodulatory effects. One of these is the nucleoside analogue gemcitabine, which is widely used in patients with lung cancer, ovarian cancer, breast cancer, mesothelioma and several other types of cancer, but with limited efficacy. We hypothesized that the immunop...
Guardado en:
Autores principales: | W Joost Lesterhuis, Joanne Salmons, Anna K Nowak, Esdy N Rozali, Andrea Khong, Ian M Dick, Julie A Harken, Bruce W Robinson, Richard A Lake |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/356226740b7c4b4bb74348ae13186b28 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
CTLA-4 blockade in the treatment of colorectal cancer with microsatellite instability
por: Diana Russo, et al.
Publicado: (2021) -
Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer
por: Clélia Coutzac, et al.
Publicado: (2020) -
Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment
por: Hong Chen, et al.
Publicado: (2021) -
Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-CTLA-4 and Doxil Combination Therapy
por: Alimohammadi R, et al.
Publicado: (2020) -
Synergistic Anti-Tumor Effect of Simvastatin Combined to Chemotherapy in Osteosarcoma
por: Adèle Mangelinck, et al.
Publicado: (2021)